Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Follicular Lymphoma (FL): full-pipeline trial registry
8 of 11 indexed Follicular Lymphoma (FL) trials are currently recruiting.
Corpus placement: #1,577 of 28,707 conditions by registered trial count.
11 US clinical trials · 8 currently recruiting · #1,577 of 28,707 conditions by registered trial count
Follicular Lymphoma (FL): 11 US clinical trials tracked, 8 recruiting.
Follicular Lymphoma (FL) is the subject of 11 registered US clinical trials on ClinicalTrials.gov, 8 of them currently open to new participants. 4 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is Nurix Therapeutics, running 2 of these trials.
Enrollment posture brief
Registry condition follicular-lymphoma-fl
OPEN 8 | RECR 73% | LATE 4 | EARLY 6 | RANK #1577 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Adult (73% recruiting · 11 trials)
Follicular Lymphoma (FL) lists 8 open slots (73% of 11 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Follicular Lymphoma (FL) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Follicular Lymphoma (FL) is recruiting above its size-band peers.
8 of 11 indexed trials (72.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Follicular Lymphoma (FL) research.
Nurix Therapeutics accounts for 2 of 11 trials (18.2%). 8 distinct sponsors appear on at least one study for this condition label.
-
Typical Follicular Lymphoma (FL) enrolment sits around 549 participants.
Median target enrolment is 549 among the 11 trials that report a genuine target (sentinel values excluded). 2 of those (18.2%) plan for fewer than 100 participants.
-
Follicular Lymphoma (FL) research is mostly interventional.
10 interventional and 1 observational studies make up this index (90.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
11 total, page 1 of 1
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
Genmab
NCT06191744
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
Regeneron Pharmaceuticals
NCT06091254
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Nurix Therapeutics
NCT05131022
A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies
Tempus AI
NCT07154823
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
Pfizer
NCT03460977
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
Nurix Therapeutics
NCT04830137
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
AstraZeneca
NCT06526793
This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma
LTZ Therapeutics
NCT07121946
A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma
Regeneron Pharmaceuticals
NCT06097364
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma
Genmab
NCT05409066
CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies
Calibr, a division of Scripps Research
NCT04450069
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 1 |
| Phase 3 | 4 |
Top Sponsors
Named interventions
Most-linked intervention names on Follicular Lymphoma (FL) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Follicular Lymphoma (FL) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Follicular Lymphoma (FL) page
11 registered trials, 8 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 8 Follicular Lymphoma (FL) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Nurix Therapeutics sponsors the most Follicular Lymphoma (FL) trials on record, review their full trial history before evaluating a specific study. See Nurix Therapeutics's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Follicular Lymphoma (FL) condition card totals 11 registered trials; most-linked intervention Rituximab; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.